Sign In
Buy MASI
$179.95
+0 (+0%)
At Close: Jun 23, 2026
HALPER SADEH LLC ENCOURAGES MASIMO CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
03:20pm, Friday, 05'th Dec 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves
Masimo Pitches 2028 Plan With 30% Operating Margins
12:09pm, Thursday, 04'th Dec 2025
Masimo Corp (NASDAQ: MASI) on Wednesday hosted its 2025 Investor Day. At the event, Masimo's management team provided an update on the company's long-term strategy.
Masimo Corporation (MASI) Analyst/Investor Day Transcript
01:13am, Thursday, 04'th Dec 2025
Masimo Corporation (MASI) Analyst/Investor Day Transcript
Masimo Hosts 2025 Investor Day and Details Strategic Roadmap for Durable Growth
04:10pm, Wednesday, 03'rd Dec 2025
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today hosted its 2025 Investor Day at the Company's headquarters. At the event, Masimo's management team provided an update on the Company's long
Masimo (MASI) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 24'th Nov 2025
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Masimo (MASI) is a Strong Growth Stock
10:46am, Monday, 24'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
iPhone Pocket, China Sales, $600 Million Patent Case And More: This Week In Appleverse
07:01am, Sunday, 23'rd Nov 2025
Apple made headlines this weekend with a record-breaking TV drama, a viral new accessory, surging iPhone 17 sales in China, and a major $600 million patent ruling.
Wall Street Analysts Believe Masimo (MASI) Could Rally 26.6%: Here's is How to Trade
10:55am, Tuesday, 18'th Nov 2025
The mean of analysts' price targets for Masimo (MASI) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Knobbe Martens Guides Masimo to $634M Win Against Apple in Patent Infringement Case
09:00am, Tuesday, 18'th Nov 2025
IRVINE, Calif. , Nov. 18, 2025 /PRNewswire/ -- A team from Knobbe Martens led medical device pioneer Masimo (NASDAQ: MASI) to a victory over Apple in a dispute involving Masimo's patented heart monito
Bridger Management LLC Lowers Holdings in Masimo Corporation $MASI
03:50am, Tuesday, 18'th Nov 2025
Bridger Management LLC reduced its position in Masimo Corporation (NASDAQ: MASI) by 14.4% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 33,641 shares o
DRC Congratulates Knobbe Martens on its $634 Million Win for Masimo
11:35am, Monday, 17'th Nov 2025
DRC congratulates Knobbe Martens on a decisive jury verdict awarding its client Masimo more than $634 million in an Apple Watch patent infringement case.
4D Advisors Offloads $7.6 Million in Masimo (MASI) Stock, Selling 45,000 Shares
11:51am, Sunday, 16'th Nov 2025
Sold 45,000 shares in Masimo, reducing reported position by $7,569,900 Transaction represents a 4.0301% change in 13F reportable assets under management (AUM) Post-trade stake: 0 shares, $0 reported v
Bank of Montreal Can Has $936,000 Position in Masimo Corporation $MASI
04:23am, Sunday, 16'th Nov 2025
Bank of Montreal Can lowered its holdings in shares of Masimo Corporation (NASDAQ: MASI) by 9.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Comm
Jury says Apple owes Masimo $634M for patent infringement
04:07pm, Saturday, 15'th Nov 2025
A federal jury in California ruled Friday that Apple must pay medical device maker Masimo $634 million for infringing a patent on blood oxygen monitoring technology.
US jury says Apple must pay Masimo $634 million in smartwatch patent case
11:16pm, Friday, 14'th Nov 2025
A federal jury in California said on Friday that Apple owes medical-monitoring technology company Masimo $634 million for infringing a patent covering blood-oxygen reading technology.
